Anika to Participate in the Sidoti Spring Virtual Investor Conference
Anika Therapeutics, a joint preservation company, will present at the Sidoti Spring Virtual Investor Conference on March 25, 2021, at 8:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Anika Therapeutics, a joint preservation company, will present at the Sidoti Spring Virtual Investor Conference on March 25, 2021, at 8:30 a.m. ET. The presentation will feature Dr. Cheryl Blanchard, President and CEO, alongside Michael Levitz, Executive Vice President and CFO. A live audio webcast will be available on Anika’s website, with an archive accessible later. Anika focuses on innovative orthopedic solutions, including osteoarthritis management and regenerative treatments.
Details
News Market Reaction – ANIK
The recorded move for ANIK in the trading session of this news was +3.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and Chief Executive Officer and Michael Levitz, Executive Vice President, Chief Financial Officer and Treasurer, will present at the Sidoti Spring Virtual Investor Conference on Thursday, March 25, 2021 at 8:30 a.m. ET.
A live audio webcast will be available in the Investor Relations section of Anika’s website, www.anika.com. An audio archive of the session will also be available on the website.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. We partner with clinicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. Anika is headquartered in Massachusetts with operations in the United States and Europe. For more information about Anika, please visit www.anika.com.
For Investor Inquiries:
Mark Namaroff
Anika Therapeutics, Inc.
Executive Director, Investor Relations and Corporate Communications
Direct: 781-457-9287
mnamaroff@anika.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.